Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | PIK3C3 | Q8NEB9 | 8/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13552996 | 0.91 | HTR1A (0.49) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL14707491 | 0.86 | HTR1A (0.52) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL13552981 | 0.84 | HTR1A (0.54) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL13552988 | 0.83 | HTR1A (0.57) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL14707508 | 0.82 | HTR1A (0.56) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL13552713 | 0.82 | HTR1A (0.51) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL13552977 | 0.81 | HTR1A (0.52) | HTR1AHTR2AHTR7HTR6PIK3C3 | |
| SCHEMBL13552978 | 0.81 | HTR1A (0.52) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL13552991 | 0.81 | HTR1A (0.54) | HTR1AHTR2AHTR7HTR6SCN9A | |
| SCHEMBL13552931 | 0.81 | HTR1A (0.53) | HTR1AHTR2AHTR7HTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | HTR1A 1574/4885HTR2A 1172/4885HTR7 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.